for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Navidea Biopharmaceuticals Inc

NAVB.A

Latest Trade

1.04USD

Change

0.02(+1.91%)

Volume

1,227

Today's Range

1.00

 - 

1.04

52 Week Range

0.94

 - 

3.12

As of on the Nyse American LLC ∙ Minimum 15 minute delay

Latest Developments

Navidea Biopharmaceuticals Reports Third Quarter 2021 Financial Results

Nov 10 (Reuters) - Navidea Biopharmaceuticals Inc <NAVB.A>::NAVIDEA BIOPHARMACEUTICALS REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS.

Navidea Biopharmaceuticals Says Jed A. Latkin Steps Down As CEO, CFO And COO

Oct 26 (Reuters) - Navidea Biopharmaceuticals Inc <NAVB.A>::NAVIDEA BIOPHARMACEUTICALS - ANNOUNCED RESIGNATION OF JED A. LATKIN AS CEO, CFO AND CHIEF OPERATING OFFICER OF CO.NAVIDEA BIOPHARMACEUTICALS - LATKIN AND CO ARE DISCUSSING TERMS OF A SEVERANCE AGREEMENT PURSUANT TO HIS EMPLOYMENT CONTRACT.NAVIDEA BIOPHARMACEUTICALS - AN OFFICE OF CEO INCLUDING 3 MEMBERS OF BOARD OF DIRECTORS HAS BEEN ESTABLISHED TO LEAD CO ON INTERIM BASIS.

Navidea Biopharmaceuticals Q2 Revenue $261,000

Aug 11 (Reuters) - Navidea Biopharmaceuticals Inc <NAVB.A>::NAVIDEA BIOPHARMACEUTICALS REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS.Q2 REVENUE $261,000.NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS FOR Q2 OF 2021 $0.09 PER SHARE.

Navidea Biopharmaceuticals Announces End-Of-Phase 2 Type B Meeting Request Granted By The FDA To Discuss Ongoing Clinical Program In Rheumatoid Arthritis

July 15 (Reuters) - Navidea Biopharmaceuticals Inc <NAVB.A>::NAVIDEA BIOPHARMACEUTICALS ANNOUNCES END-OF-PHASE 2 TYPE B MEETING REQUEST GRANTED BY THE FDA TO DISCUSS ONGOING CLINICAL PROGRAM IN RHEUMATOID ARTHRITIS.NAVIDEA BIOPHARMACEUTICALS INC - MEETING WILL TAKE PLACE ON SEPTEMBER 1, 2021, VIA CONFERENCE CALL.NAVIDEA BIOPHARMACEUTICALS INC - MEETING WITH FDA WILL BE CENTERED ON DISCUSSION OF RESULTS FROM COMPANY'S COMPLETED PHASE 2B NAV3-31 STUDY.

Navidea Biopharmaceuticals Reports Qtrly Loss Per Share $0.11

May 11 (Reuters) - Navidea Biopharmaceuticals Inc <NAVB.A>::NAVIDEA BIOPHARMACEUTICALS REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS.Q1 REVENUE $124,000.QTRLY LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE (BASIC AND DILUTED) $0.11.

Navidea Biopharmaceuticals Announces Changes To Board Of Directors Composition

May 5 (Reuters) - Navidea Biopharmaceuticals Inc <NAVB.A>::NAVIDEA BIOPHARMACEUTICALS ANNOUNCES CHANGES TO BOARD OF DIRECTORS COMPOSITION.NAVIDEA BIOPHARMACEUTICALS - MICHAEL RICE, CO'S CHAIR OF BOARD, ADAM CUTLER HAVE RETIRED FROM THEIR POSITIONS ON NAVIDEA'S BOARD.NAVIDEA BIOPHARMACEUTICALS INC - KATHY ROUAN HAS BEEN APPOINTED AS CHAIR OF BOARD FOLLOWING MICHAEL RICE'S RETIREMENT.

Navidea Biopharmaceuticals Reports Fourth Quarter And Full Year 2020 Financial Results

March 24 (Reuters) - Navidea Biopharmaceuticals Inc <NAVB.A>::NAVIDEA BIOPHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS.Q4 REVENUE $219,000 VERSUS $119,000.Q4 LOSS PER SHARE $0.11.

Navidea Biopharmaceuticals Announces Submission Of Formal Type B Meeting Request With FDA And Launch Of Nav3-32 Phase 2B Trial In Rheumatoid Arthritis

Feb 8 (Reuters) - Navidea Biopharmaceuticals Inc <NAVB.A>::NAVIDEA BIOPHARMACEUTICALS ANNOUNCES SUBMISSION OF FORMAL TYPE B MEETING REQUEST WITH FDA AND LAUNCH OF NAV3-32 PHASE 2B TRIAL IN RHEUMATOID ARTHRITIS.NAVIDEA BIOPHARMACEUTICALS INC - FDA HAS GRANTED TYPE B MEETING AND HAS REQUESTED SUBMISSION OF BRIEFING BOOK.NAVIDEA BIOPHARMACEUTICALS INC - FDA WILL NOW REVIEW COMPANY'S FORMAL BRIEFING DOCUMENTS CONTAINING RESULTS FROM NAV3-31 PHASE 2B STUDY.NAVIDEA BIOPHARMACEUTICALS - EXPECTS FORMAL FEEDBACK FROM FDA WITHIN NEXT SEVERAL MONTHS AND A POTENTIAL LAUNCH OF PIVOTAL PHASE 3 STUDY IN Q2 OF 2021.

Navidea Biopharmaceuticals Reports Q3 Loss Per Share Of $0.13

Nov 12 (Reuters) - Navidea Biopharmaceuticals Inc <NAVB.A>::NAVIDEA BIOPHARMACEUTICALS REPORTS THIRD QUARTER AND YEAR-TO-DATE 2020 FINANCIAL RESULTS.Q3 REVENUE $268,000 VERSUS $237,000.Q3 LOSS PER SHARE $0.13.

Navidea Biopharma Files For Shelf Of Up To 2.4 Mln Shares Of Common Stock

Aug 25 (Reuters) - Navidea Biopharmaceuticals Inc <NAVB.A>::NAVIDEA BIOPHARMACEUTICALS INC FILES FOR SHELF OF UP TO 2.4 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up